METHODS, COMPOUNDS, COMPOSITIONS AND VEHICLES FOR DELIVERING 3-AMINO-1-PROPANESULFONIC ACID
申请人:Kong Xianqi
公开号:US20080146642A1
公开(公告)日:2008-06-19
The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.
Methods, compounds, compositions and vehicles for delivering 3-amino-1-propanesulfonic acid
申请人:BHI Limited Partnership
公开号:EP2862581A2
公开(公告)日:2015-04-22
The invention relates to methods, compounds, compositions and vehicles for delivering 3-amino-1 -propanesulfonic acid (3APS) in a subject, preferably a human subject. The invention encompasses compounds that will yield or generate 3APS, either in vitro or in vivo. Preferred compounds include amino acid prodrugs of 3APS for use, including but not limited to, the prevention and treatment of Alzheimer's disease.
Disclosed herein are methods and compositions for treating, ameliorating, and/or preventing Alzheimer's disease in ApoE4-postitive patients using particular compounds and compositions thereof.
Isotope-enriched 3-amino-1-propanesulfonic acid derivatives and uses thereof
申请人:Risen (Suzhou) Pharma Tech Co., Ltd.
公开号:US10472323B2
公开(公告)日:2019-11-12
There are provided isotope-enriched compounds of Formula (I) and pharmaceutically acceptable salts or esters thereof, as well as pharmaceutical compositions thereof and methods of use thereof for prevention and treatment of amyloid-β related diseases, such as Alzheimer's disease.
R1R2X—CR2—CH2—CH2—SO3H (I)
Methods of treating neurodegenerative disorders in a particular population
申请人:ALZHEON, INC.
公开号:US11191742B2
公开(公告)日:2021-12-07
Disclosed herein are methods for treating, ameliorating, and/or preventing Alzheimer's Disease in a specific patient population using tramiprosate, valyl-3-amino-1-propanesulfonic acid, or a pharmaceutically acceptable salt thereof based upon a combination of APOE4 status and disease severity.